Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan;12(1):14-20.
doi: 10.3988/jcn.2016.12.1.14. Epub 2015 Nov 26.

Clinical Trials of Adult Stem Cell Therapy in Patients with Ischemic Stroke

Oh Young Bang  1   2
Affiliations
Review

Clinical Trials of Adult Stem Cell Therapy in Patients with Ischemic Stroke

Oh Young Bang. J Clin Neurol. 2016 Jan.

Abstract

Stem cell therapy is considered a potential regenerative strategy for patients with neurologic deficits. Studies involving animal models of ischemic stroke have shown that stem cells transplanted into the brain can lead to functional improvement. With current advances in the understanding regarding the effects of introducing stem cells and their mechanisms of action, several clinical trials of stem cell therapy have been conducted in patients with stroke since 2005, including studies using mesenchymal stem cells, bone marrow mononuclear cells, and neural stem/progenitor cells. In addition, several clinical trials of the use of adult stem cells to treat ischemic stroke are ongoing. This review presents the status of our understanding of adult stem cells and results from clinical trials, and introduces ongoing clinical studies of adult stem cell therapy in the field of stroke.

Keywords: clinical trials; stem cells; stroke.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has no financial conflicts of interest.

Figures

Fig. 1
Fig. 1. Mechanisms of action of mesenchymal stem cells in stroke recovery.
Fig. 2
Fig. 2. Number of papers on stem cells and stroke.
Fig. 3
Fig. 3. Summary table for the risk of bias from different items for each clinical trial of stem cells in patients with stroke. BM: bone marrow, MNCs: mononuclear cells, MSCs: mesenchymal stem cells, NSCs: neural stem/progenitor cells.
Fig. 4
Fig. 4. Number and types of stem cells in clinical trials for patients with stroke. allo: allogeneic, auto: autologous, BM: bone marrow, MSCs: mesenchymal stem cells, SC: stem cell.
See this image and copyright information in PMC

References

    1. Chopp M, Li Y. Treatment of neural injury with marrow stromal cells. Lancet Neurol. 2002;1:92–100. - PubMed
    1. Chang DJ, Lee N, Park IH, Choi C, Jeon I, Kwon J, et al. Therapeutic potential of human induced pluripotent stem cells in experimental stroke. Cell Transplant. 2013;22:1427–1440. - PubMed
    1. Dihné M, Hartung HP, Seitz RJ. Restoring neuronal function after stroke by cell replacement: anatomic and functional considerations. Stroke. 2011;42:2342–2350. - PubMed
    1. Chen X, Li Y, Wang L, Katakowski M, Zhang L, Chen J, et al. Ischemic rat brain extracts induce human marrow stromal cell growth factor production. Neuropathology. 2002;22:275–279. - PubMed
    1. Li WY, Choi YJ, Lee PH, Huh K, Kang YM, Kim HS, et al. Mesenchymal stem cells for ischemic stroke: changes in effects after ex vivo culturing. Cell Transplant. 2008;17:1045–1059. - PubMed

LinkOut - more resources